Abstract:The TP53 gene encodes p53, a transcription factor involved in tumor suppression. However, TP53 also encodes other protein isoforms, some of which can disrupt the tumor suppressor functions of p53 even in the absence of TP53 mutations. In particular, elevated levels of the Δ133 TP53 mRNA are detected in many cancer types and can be associated with poorer disease-free survival. We investigated the mechanisms of action of the two proteins translated from the Δ133 TP53 mRNA: the Δ133p53α and Δ160p53α isoforms, both of which retain the oligomerization domain of p53. We discovered that the Δ133p53α and Δ160p53α isoforms adopt an altered conformation compared to full-length p53, exposing the PAb240 epitope (RHSVVV), which is inaccessible to the PAb240 antibody in the functional conformation of p53 (reactive to PAb1620). The Δ133p53α and/or Δ160p53α isoforms form hetero-oligomers with p53, regulating the stability, the conformation and the transcriptional activity of the p53 hetero-oligomers. Under basal conditions, Δ133p53α and Δ160p53α, in complex with p53, prevent proteasome-dependent degradation leading to the accumulation of PAb240 reactive Δ133p53α/Δ160p53α/p53 hetero-oligomers without increasing p53 transcriptional activity. Conversely, depletion of endogenous Δ133p53α isoforms in human fibroblasts is sufficient to restore p53 transcriptional activity, towards p53-target genes involved in cell cycle arrest. In the DNA damage response (DDR), PAb240 reactive Δ133p53α/Δ160p53α/p53 hetero-oligomers are highly phosphorylated at Ser15 compared to PAb1620-reactive p53 complexes devoid of Δ133p53α and Δ160p53α. This suggests that PAb240-reactive p53 hetero-oligomers integrate DNA damage signals. Δ133p53α accumulation is a late event in the DDR that depends on p53, but not on its transcriptional activation. The formation of Δ133p53α and p53 complexes increases at later DDR stages. We propose that Δ133p53α isoforms regulate p53 conformation as part of the normal p53 biology, modulating p53 activity and thereby adapting the cellular response to the cell signals.

Interaction Between P53 and TRF1、TRF2 and Analysis of Binding Domain of P53 in vitro

In Vitro Binding of P53 and Telomeric Repeat Factor 2

[The Molecular Interaction Between P53 and Telomeric Repeat Binding Protein 1 in Vitro].

In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.

The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins.

Interaction Between P53 N Terminus and Core Domain Regulates Specific and Nonspecific DNA Binding.

Interaction of p53 with the Δ133p53α and Δ160p53α isoforms regulates p53 conformation and transcriptional activity

Mdm-2 binding and TAFII31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

Expression, purification, and in vitro mitochondrial interaction analysis of full-length and truncated human tumor suppresser p53

Studies of Interaction of Tumor Suppressor P53 with Apo-Mt Using Surface Plasmon Resonance

Tumor suppressor p53 cross-talks with TRIM family proteins

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Interaction of Tumor Suppressor P53 with DNA and Proteins.

The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.

Wild-type P53 Regulates Human Ribonucleotide Reductase by Protein-Protein Interaction with P53r2 As Well As Hrrm2 Subunits.

NMR Studies of the Interaction Between Human Programmed Cell Death 5 and Human P53.

TRAF6 Restricts P53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression.

Interaction of P53 and Inhibitor of NF-κB Alpha and Their Shuttling Between Cytoplasm and Nucleus Observed in Living Cells

Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study

A Global Map of P53 Transcription-Factor Binding Sites in the Human Genome.